<DOC>
	<DOCNO>NCT01623115</DOCNO>
	<brief_summary>Alirocumab ( SAR236553/REGN727 ) fully human monoclonal antibody bind PCSK9 ( proprotein convertase subtilisin/kexin type 9 ) . Primary Objective study : To evaluate effect alirocumab low-density lipoprotein cholesterol ( LDL-C ) level 24 week treatment comparison placebo . Secondary Objectives : - To evaluate effect alirocumab comparison placebo LDL-C time point - To evaluate effect alirocumab lipid parameter - To evaluate safety tolerability alirocumab</brief_summary>
	<brief_title>Efficacy Safety Alirocumab ( SAR236553/REGN727 ) Versus Placebo Top Lipid-Modifying Therapy Patients With Heterozygous Familial Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy</brief_title>
	<detailed_description>The maximum study duration plan 89 week per participant include participant successfully complete 78-week treatment period possibility join open-label extension study ( LTS13463 , NCT01954394 ) end treatment period .</detailed_description>
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Hyperlipoproteinemia Type II</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Inclusion criterion : Participants heterozygous familial hypercholesterolemia adequately control lipidmodifying therapy Exclusion criterion : Age &lt; 18 year legal age adulthood , whichever great LDLC &lt; 70 mg/dL ( 1.81 mmol/L ) cardiovascular disease LDLC &lt; 100 mg/dL ( 2.59 mmol/L ) without cardiovascular disease Fasting serum triglyceride &gt; 400 mg/dL ( 4.52 mmol/L ) Known history homozygous familial hypercholesterolemia The information intend contain consideration relevant participant 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>PCSK9</keyword>
</DOC>